 NEWTON, Mass. and GENEVA, Aug. 09, 2021 GLOBE NEWSWIRE -- Acer Therapeutics Inc. Nasdaq: ACER Acer, a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, and RELIEF THERAPEUTICS Holding AG SIX: RLF, OTCQB: RLFTF Relief, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, today announced the submission of a New Drug Application NDA to the U.S. Food and Drug Administration FDA for ACER-001 sodium phenylbutyrate for the treatment of Urea Cycle Disorders UCDs. ACER-001 is a nitrogen-binding agent in development for use as adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase CPS, ornithine transcarbamylase OTC, or argininosuccinic acid synthetase AS. 